Cross-Sector entity
Ben Lamm is most often covered alongside Colossal Biosciences, which appears in 4 of these 4 stories. That works out to roughly 0.2 stories per week across a 140-day span. The busiest single day carried 2. Coverage clusters in funding, which accounts for 2 of those 4, with the remainder spread across 2 other categories.
4 verified stories tracked
Last mentioned: Jul 21, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Ben Lamm is most often covered alongside Colossal Biosciences, which appears in 4 of these 4 stories. That works out to roughly 0.2 stories per week across a 140-day span. The busiest single day carried 2. Coverage clusters in funding, which accounts for 2 of those 4, with the remainder spread across 2 other categories. This profile follows 4 Cross-Sector stories mentioning Ben Lamm across the period from March 4, 2026 to July 21, 2026. Each carries 3 original sources on average.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ben Lamm. Shared-story counts are live from our verified record — not editorial picks.
Target Birth Date
Projected window for the birth of the first mammoth-elephant hybrid calf.
Funding talks reported at $20B–$30B valuation
Axios and TechCrunch report Colossal is in discussions to raise new capital at a valuation between $20 billion and $30 billion.
Tasmanian devil cancer partnership launched
Colossal Foundation partners with University of Tasmania to combat contagious facial cancer in Tasmanian devils.
Artificial womb tech expected ready in 2027
CEO Ben Lamm tells Rolling Stone the technology could be spun off for human fertility applications.
Bluebuck antelope added as sixth target species
Colossal expands de-extinction pipeline to include bluebuck antelope.
Astromech spinout achieves $2B valuation
AI-driven biology predictive modeling company reaches unicorn status just months after launch.
Dubai Biovault
Colossal announces the opening of a major genetic preservation facility in Dubai.
Colossal valued at $10.2B after dire wolf project reveal
Investors justify valuation based on broad technology platform, not just de-extinction.
Series B Funding
Total funding surpasses $225M, valuing the company at over $1 billion.
Dodo Project Announced
The company expands its portfolio to include the de-extinction of the dodo bird.
Company Launch
Colossal Biosciences officially launches with $15M in seed funding to revive the woolly mammoth.
Venture capital’s most audacious bet, Colossal Biosciences, is seeking a valuation of $20–$30 billion — a nearly 3x jump — as it generates revenue, spins out high-value startups, and turns its de-extinction mission into a startup factory with government clients and AI-driven assets.
Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
Source: TechCrunch · Marina Temkin (us)
Colossal Biosciences is advancing its mission to revive the woolly mammoth by 2028, sparking intense debate over the ethics of de-extinction. While the startup has secured over $225 million in venture capital, critics argue the project is a costly distraction from urgent conservation efforts for living species.
Colossal Biosciences is advancing its ambitious plan to 'de-extinct' the woolly mammoth using CRISPR technology, sparking intense debate over ecological ethics and resource allocation. While the company frames the project as a climate solution, critics argue it distracts from urgent conservation efforts for existing endangered species.
Source: iowapublicradio.org · wdiy.org
